OptimizeRx announces Chair retirement; Lynn O'Connor Vos appointed Chair, Catherine Klema added as director

OptimizeRx Corp

Gus Halas retired as Chairperson effective Jan 24, 2024, after nearly a decade of service.
Lynn O'Connor Vos appointed Chairperson, also joins Nominating & Governance, Compensation, and Audit committees.
Board increased to 7 members; Catherine M. Klema appointed as director and member of Audit and Compensation committees.
Klema receives annual cash retainer $40,000, equity grant $150,000, plus additional committee retainers ($10k Audit, $5k Comp).

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Catherine M. Klema

Director

OPRX · OptimizeRx Corp

Effective: 2024-01-24
Filed: January 26, 2024, 6:59 PM ET

Effective January 24, 2024, the Board increased the size of the Board to seven (7) members and, upon the recommendation of the Board’s Nominating & Governance Committee, appointed Catherine M. Klema to serve as a director of the Company

Role change

Lynn O'Connor Vos

Chairperson of the Board

OPRX · OptimizeRx Corp

Effective: 2024-01-24
Filed: January 26, 2024, 6:59 PM ET

Effective January 24, 2024, the Board appointed Lynn O’Connor Vos, a director of the Company, to serve as Chairperson of the Board

Departed

Gus Halas

Chairperson of the Board

OPRX · OptimizeRx Corp

Effective: 2024-01-24
Successor: Lynn O'Connor Vos
Filed: January 26, 2024, 6:59 PM ET

Effective January 24, 2024, Gus Halas retired from his position as Chairperson of the Board of Directors

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Catherine M. Klema was appointed as Director at OptimizeRx Corp.

Action: appointed
Role: Director

Exact text from the filing

Effective January 24, 2024, the Board increased the size of the Board to seven (7) members and, upon the recommendation of the Board’s Nominating & Governance Committee, appointed Catherine M. Klema to serve as a director of the Company

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Lynn O'Connor Vos was appointed as Chairperson of the Board at OptimizeRx Corp.

Action: appointed
Role: Chairperson of the Board

Exact text from the filing

Effective January 24, 2024, the Board appointed Lynn O’Connor Vos, a director of the Company, to serve as Chairperson of the Board

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Gus Halas retired as Chairperson of the Board at OptimizeRx Corp.

Action: retired
Role: Chairperson of the Board

Exact text from the filing

Effective January 24, 2024, Gus Halas retired from his position as Chairperson of the Board of Directors

View on SEC.gov

OptimizeRx Corp filing history →

Source: SEC EDGAR

accession 0001213900-24-006959

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.